Page 1678 - Clinical Small Animal Internal Medicine

1616 Index

lavage 1032 prognosis 948 imaging 653
VetBooks.ir laxatives 612–613, 616 signalment 946 malignancies/neoplasia 684–686
interpretation of clinical
public health implications
see also bronchoalveolar lavage
948–949
pathology 653, 654
LC see lymphocytic cholangitis
L‐carnitine deficiency 188, 192 treatment 947–948 metabolic diseases 677–683
LCP see Legg–Calvé–Perthes leukemia see feline leukemia virus newer tests 653
LDDS see low‐dose dexamethasone leukemia inhibitory factor and receptor pathophysiology of important clinical
suppression (LIF/LIFR) 51 presentations 641–644
LDL see low‐density lipoprotein leukoencephalomyelopathy portal hypertension 643
left atrial enlargement (LEM) 782 septic shock 423
cardiovascular disease 130, leukopenia 870 serology 653
134–137 leukopheresis 1370, 1371 signalment 644–645
feline myocardial disease leuteinizing hormone (LH) toxic diseases 683–684
271, 273 36–38 urinalysis 653
valvular heart disease 246–247 level of consciousness (LOC) urolithiasis 1129
left bundle branch block (LBBB) 448, 753 see also hepatic; hepatobiliary
172–173, 174 L‐form bacteria 931–935 disease
left‐sided congestive heart LH see luteinizing hormone liver failure 1071
failure 131–132, 134, 136–137 lice see pediculosis liver flukes 690
left ventricular eccentric lichenification liver function tests 649–652,
hypertrophy 246 approach to the dermatologic 707–708
left ventricular enlargement 130, patient 1386 liver lobe torsion 667
134–135, 137 atopic dermatitis 1405 liver pseudofunction tests 707
left ventricular hypertrophy 268 cutaneous adverse food livestock 4–5
left ventricular outflow tract (LVOT) reactions 1420 LMN see lower motor neuron
obstruction 265, 415 LIF/LIFR see leukemia inhibitory factor LMWH see low molecular weight
Legg–Calvé–Perthes (LCP) and receptor heparin
disease 1547–1548 limbal melanoma 1263–1264 lobular orbital adenoma 1267
leiomyoma/leiomyosarcoma limb function assessment 752, 752 LOC see level of consciousness
esophageal and stomach lincosamides 1046 localized hepatomegaly 661, 662
cancers 1283, 1285 linear foreign bodies 494, 494 longitudinal observational studies
intestinal cancers 1287, 1289, linear IgA disease (LAD) 1428 case–control studies 21–23
1291–1292 lingual hemangiosarcoma 1341 clinical decision making 18–25
leishmaniosis 1009–1011 lipid metabolism 650–651 clinical trials 23–25
cutaneous manifestations of systemic see also hepatic lipidosis cohort studies 19–21, 20
disease 1485, 1486 liver disease 641–658 loop diuretics 417
diagnosis 1010–1011 acquired portosystemic shunts 643 loss of nociception 818
epidemiology 1010 anatomy and physiology 641 lotions 1398
etiology/pathophysiology 1009–1010 ascites 643 low‐density lipoprotein (LDL) 1370
history and clinical signs 1010 biochemical evaluation 645–652 low‐dose dexamethasone
signalment 1010 canine inflammatory liver suppression (LDDS) 31–32,
treatment and prognosis 1011 disease 695–703 32, 53–54, 54, 56
LEM see leukoencephalomyelopathy cholestasis 641–642 lower airway 290–291
lens‐induced uveitis 95 coagulopathy 644 lower motor neuron (LMN)
leprosy/leproid granuloma cytology 655–656 731–735, 807, 1184–1186
syndromes 980–983 diagnosis 645–658 lower urinary tract (LUT) 1124,
leptospirosis 945–949 feline inflammatory liver 1127–1128, 1136–1149
acute kidney injury 1091, 1093, disease 687–693 low‐fat diet 589
1098 gastroduodenal ulceration 644 low molecular weight heparin
canine inflammatory liver disease genetics and genetic testing 653 (LMWH) 321–322
696, 702 hematology 652–653 L‐type calcium channels 175–176
diagnosis 946–947 hepatic encephalopathy 643–644, lung cancers
epidemiology 945–946 644 diagnosis 1279–1280
etiology/pathophysiology 945 histopathology 656–658 epidemiology 1278–1279
history and clinical signs 946 history and clinical signs 645, 646 etiology/pathophysiology 1278
prevention 948 icterus 642, 642 history and clinical signs 1279